http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2008038278-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e10a727e1ae8b572defd5cdff461e7a9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59ec9c1fad5bad108cefaf4f03b6ebf7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3046fcbb3efc6e35fe65c01709f4e3dc |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N9-1029 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-00 |
filingDate | 2007-02-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2de90ca8d06a87deddad683712b5c391 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8124ac88cc92954b52dd5bee34844cbb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1f2f67297b26de5236a1dc7dfea5cf94 |
publicationDate | 2008-02-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2008038278-A1 |
titleOfInvention | GPAT3 encodes a mammalian, microsomal acyl-coa:glycerol 3- phosphate acyltransferase |
abstract | The present invention provides isolated and purified polynucleotides and polypeptides related to mouse and human microsomal acyl-CoA:glycerol 3-phosphate acyltransferase 3 (GPAT3) and their uses in modulating triacylglycerol (TAG) levels in a cell or sample of interest. The invention also provides GPAT3 agonists and antagonists, e.g., GPAT3 polynucleotides and polypeptides, antibodies to GPAT3 (agonistic and antagonistic antibodies), GPAT3 inhibitory polypeptides, and GPAT3 inhibitory polynucleotides. The present invention is also directed to novel methods for diagnosing, prognosing, monitoring, treating, ameliorating and/or preventing conditions related to GPAT3, TAG synthesis (or accumulation), or the synthesis (or accumulation) of TAG precursors (e.g., MAG, LPA, PA, and/or G3P). These GPAT3-associated conditions include, but are not limited to, dyslipidemia (e.g., hyperlipidemia, hypertriglyceridemia, Type III hyperlipidemia), obesity, hypercholesterolemia, hepatic steatosis, cancer, skin disorders associated with altered lipid metabolism (e.g., acne vulgaris, dry skin), adiposity, type 2 diabetes (and complications associated therewith, such as dermopathy, retinopathy, neuropathy, and nephropathy), insulin resistance, hyperinsulinemia, hypertension, cardiovascular disease, atherosclerosis, stroke, thrombosis, lipodystrophy, lipopenia, Reye's syndrome, Cushing's syndrome, metabolic syndrome (e.g., syndrome X), eating disorders (e.g., anorexia, bulimia), skin homeostasis, disorders related to energy storage, nutrient absorption, and lipid metabolism, reduced or absent lactation, and low preterm birth weight (and complications thereof, such as defects in neural development). |
priorityDate | 2006-02-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 445.